Lucentis FDA Approval History
FDA Approved: Yes (First approved June 30, 2006)
Brand name: Lucentis
Generic name: ranibizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Macular Degeneration; Macular Edema; Diabetic Macular Edema; Diabetic Retinopathy; Myopic Choroidal Neovascularization
Lucentis (ranibizumab) is a humanized anti-VEGF antibody fragment indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
Development timeline for Lucentis
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.